Safety and clinical effects of IDX12899 in HIV-1 infection

Submission date	Recruitment status	Prospectively registered
21/12/2007	No longer recruiting	☐ Protocol
Registration date 06/02/2008	Overall study status Completed	Statistical analysis plan
		Results
Last Edited	Condition category	Individual participant data
18/09/2008	Infections and Infestations	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Carlos Zala

Contact details

Hospital Privado Modelo 1811 Julio A Roca Street Florida B1602DBG Partido de Vicente López Buenos Aires Argentina

+54 11 4792 7023 clinicaltrials@idenix.com

Additional identifiers

Protocol serial number NV-05A-002

Study information

Scientific Title

A phase I/IIa, double-blind study to evaluate the safety and tolerability, antiretroviral activity, pharmacokinetics and pharmacodynamics of IDX12899 in antiretroviral treatment-naïve HIV-1-infected subjects

Study objectives

The safety profile and antiviral activity demonstrated in vitro by IDX12899 predicts acceptable safety and antiviral activity in HIV-1-infected patients.

As of 27/06/2008, the anticipated end date of this trial has been updated. The previous anticipated end date was 28/02/2008.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Independent Ethics Committee in Clinical Research c/o Dr Virgilio G. Foglia Registration OHRP No: IRB 00001678 - USA.

Tucumán 335 -70 piso "D" - (C1049AAG) Buenos Aires, Argentina) approval ref 653/65/2007.

Study design

Phase I/IIa, randomized, double-blind, placebo-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic HIV-1 infection

Interventions

From 27/06/2008: Sequential cohorts of 10 subjects will be randomised at an 8:2 ratio to receive IDX12899 (oral capsule) 800 mg, 400 mg, 200 mg and 100 mg or placebo once daily for 7 days.

Before 27/06/2008: Subjects will be randomised at an 8:2 ratio to receive IDX12899 (oral capsule) 800 mg once daily or placebo for 7 days.

Intervention Type

Drug

Phase

Phase I/II

Drug/device/biological/vaccine name(s)

IDX12899 (antiretroviral drug)

Primary outcome(s)

- 1. Proportion of subjects experiencing adverse events and laboratory abnormalities, followed-up until Study day 14 (7 days after the last dose of study drug)
- 2. Decrease from baseline through Day 8 in plasma HIV-1 RNA

Key secondary outcome(s))

- 1. Change from baseline at Day 8 in Reverse Transcriptase (RT) sequences of HIV-1
- 2. Change from baseline at Day 8 in CD4+ and CD8+ T-lymphocyte cell count
- 3. Plasma concentrations and calculated PharmacoKinetic (PK)/PharmacoDynamic (PD) parameters. The last PK sample is collected on Day 8 (24 hours after the last dose of study drug)
- 4. Profiling of metabolites. The last PK sample is collected on Day 8 (24 hours after the last dose of study drug)

Completion date

30/09/2008

Eligibility

Key inclusion criteria

- 1. Male or Female, 21 to 65 years of age
- 2. Female of non-childbearing potential
- 3. Plasma HIV-1 RNA value >=5000 copies/mL
- 4. CD4+ count >=200 cells/mm3
- 5. Subject is antiretroviral treatment-naïve
- 6. Subject agrees to start a standard HAART regimen on Day 8 of the study or Kaletra® monotherapy for 28 days within 24 hours after the last dose of study medication
- 7. Subject has provided written informed consent to participate in the study

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

- 1. Pregnant or breastfeeding
- 2. Male of reproductive potential and unwilling to use double barrier method of contraception during and for at least 30 days after the last dose of the study drug
- 3. Co-infection with acute hepatitis A (HAV), chronic hepatitis B (HBV) or active hepatitis C (HCV)
- 4. Alcohol or illicit drug abuse, or history of alcohol abuse or illicit drug abuse within the preceding one year
- 5. Potential allergy to the study medication or the follow-up HAART or Kaletra® therapy
- 6. Received an immunomodulating agent or immunotherapeutic vaccine within 30 days before Day -1
- 7. Receiving co-medication that is a known substrate, inhibitor and/or inducer of CYP3A4
- 8. Enrollment in another clinical study of an investigational agent
- 9. Subject who has received any investigational drug within 90 days prior to Day -1
- 10. History of AIDS-defining illness
- 11. History of or currently active disease that may put the subject at risk because of participation

in this study

- 12. Subject with an intestinal malabsorption
- 13. Subject with a pre-existing Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) drug resistance based on genotyping at Screening
- 14. Subject who has had a significant blood loss 30 days prior to Day -1
- 15. Subject has any of the following laboratory parameters at Screening: hemoglobin <8.5 g/dL, neutrophil count <1,000 cells/mm3, platelet count <100,000 cells/mm3, serum creatinine > the Upper Limit of Normal (ULN), ASpartate aminoTransferase (AST) or ALanine aminoTransferase (ALT) >=2.5 x ULN, Total bilirubin >ULN

Date of first enrolment 03/01/2008

Date of final enrolment 30/09/2008

Locations

Countries of recruitmentArgentina

Study participating centre Hospital Privado Modelo Buenos Aires Argentina

Sponsor information

Organisation

Idenix Pharmaceuticals (USA)

ROR

https://ror.org/02891sr49

Funder(s)

Funder type

Industry

Funder Name

Idenix Pharmaceuticals (USA)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet
Participant information sheet
11/11/2025 No Yes